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Ssuch a difference because of the limitations imposed on sta-
tistical analysis by the small sample size.
In conclusion, this retrospective analysis of surgical re-
section after induction therapy for clinical stage IIIA
NSCLC demonstrates that surgical resection can be per-
formed safely with long-term survival for appropriate pa-
tients. Our study suggests that the ideal patient who
would benefit maximally from surgical resection after in-
duction therapy for clinical IIIA disease is young, requires
only lobectomy for complete resection, and has evidence
of mediastinal downstaging. Our analysis, however, has in-
sufficient data to suggest that patients with residual N2 dis-
ease after induction therapy should be excluded from
surgical resection. Five-year survival even for nonideal pa-
tients, such as patients who undergo pneumonectomy with
residual N2 disease, is approximately 20%, which may be
acceptable for appropriate patients as long as operativemor-
tality can be kept low.References
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Dr Gail E. Darling (Toronto, Ontario, Canada). Dr Paul, I
thank you and your coauthors for providing me with the manu-
script and your presentation in advance of the meeting. I compli-
ment you for tackling this topic and also for your very
commendable operative mortality, which is particularly outstand-
ing for this group of patients.ardiovascular Surgery c Volume 141, Number 1 55
General Thoracic Surgery Paul et al
G
T
SDuring the study interval, you found 136 patients with N2 dis-
ease who underwent surgical resection after induction. How many
patients with N2 disease were evaluated in your center, and how
did you select patients for surgery?
Dr Paul.During that interval, probably around 450 patients had
positive results of mediastinoscopy; however, those included pa-
tients who had likely stage III disease and some patients who prob-
ably underwent a mediastinoscopy for diagnosis as well. Because
we are a referral center, we also get patients sent to us who have
had positive results of mediastinoscopy at an outside institution
and are coming in after induction therapy to undergo resection.
So it’s a fairly low number of patients who actually finally made
it to surgery. In our series, it was probably around 20% to 25%.
Our selection criteria are basically that patients must have good
functional status and the cardiopulmonary ability to tolerate resec-
tion and also must have at least stable disease in response to induc-
tion therapy.
Dr Darling. Thank you. I noticed that 11% of patients had mul-
tiple-station N2 disease.
Dr Paul. Correct.
Dr Darling. So you did not exclude those patients from consid-
eration for surgery?
Dr Paul. We did not.
Dr Darling. Among patients who did not have confirmation of
N2 disease before induction, was there any evidence of tumor re-
gression on final pathologic examination? We know that 40% of
enlarged nodes on CT scan are actually benign, and 20% to 25%
of hot nodes on PET scan are actually benign. So how can you
be sure that those 22 who didn’t actually undergo invasive staging
before induction really did have N2 disease?
Dr Paul. Of those 22 patients, 11 patients had either N1 or N2
disease in the final pathologic specimen, so about 50%. Specifi-
cally, 7 of those 22 patients had N2 disease pathologically in the
specimen. As well, we compared the survival of patients who un-
derwent mediastinoscopy and patients who had disease diagnosed
by radiographic criteria, and survival did not statistically differ be-
tween these groups.
Dr Darling. Did you consider analyzing the whole group with-
out those patients?
Dr Paul. Sure.We also did the analysis excluding all 22 patients
who had diagnoses based solely on radiographic criteria, and es-
sentially we came up with the same conclusions. Our multivariate
analysis showed age, extent of resection, and residual N2 as fac-
tors; however, the P value for one of them changed to be greater
than .05. So it was a trend as opposed to being significant.
Dr Darling. In light of the importance of the mediastinal down-
staging, do you have any recommendations for us in terms of
whether we should be restaging the mediastinum? Would you
not offer surgery to patients who have persistent N2 disease?
DrPaul.Our policy has been not to restage themediastinum, be-
cause we do offer resection to patients who have persistent N2 dis-
ease. We believe that a 20% 5-year survival is better than nothing.
Dr Robert J. Cerfolio (Birmingham, Ala). But you just showed
that they did poorly. Are you going to change your recommenda-
tions from your own data?
Dr Paul. It depends on what the alternative is. If they have no
viable alternative therapy that they can receive, we’re not going
to change.56 The Journal of Thoracic and Cardiovascular SurgeDr Mark J. Krasna (Towson, Md). Congratulations, Dr Paul,
on an excellent presentation, and congratulations to you and
your group for amazing mortality statistics.
I have a comment and a question. I think what you have done is
help us to refine further who are the patients we should operate on
after induction therapy. My personal bias, and that of Drs Cerfo-
lio, Weder, and Venuta, 3 other people in the room who presented
in the past year on either pneumonectomy or lobectomy, is that
chemotherapy and radiation together might give you a better path-
ologic response and might give you better long-term survival, but
I don’t think that’s the issue. You have done a very good job,
though, in showing us exactly what Dr Cerfolio pointed out.
That is, if you can determine up front that you have patients
with persistent positive nodes, don’t operate on them. If you
find out up front that there are patients who have other predictors
for poor long-term outcome, don’t operate on them. We should
only be operating on those patients for whom we can document
downstaging and who had a good response. So I think the ques-
tion of chemoradiotherapy versus chemotherapy would be inter-
esting, but the same issue comes up. You should really be
tackling those.
My question relates to, and I guess Dr Meyers needs to help us
statistically, I’m sure there is statistical error. You had only 1 death.
How could one death out of 27 pneumonectomies in the overall
pneumonectomies and lobectomies still have survived both univar-
iate and multivariate analysis to be an independent prognosticator?
I think there has got to be some other explanation.
Dr Paul. The numbers are small, and we ran the numbers in var-
ious different ways, and I think it’s a statistical thing that happens
when numbers are that small.
Dr Krasna. I would suggest that the last conclusion may not in
fact be upheld by that 1 death. I think there are enough con-
founders, although I can’t explain them. The conclusion that pneu-
monectomy in fact is a poor independent prognosticator, I don’t
know whether that is upheld by that 1 death.
Dr Altorki. The issue of operating on patients with residual N2
disease is obviously controversial. In reality, however, although
20% survival in such patients is not great, I don’t know that there
are many other options out there to treat patients who have persis-
tent N2 disease that is not responsive to chemotherapy. So I think at
the very least, we can all agree that the question is open for discus-
sion. If there were a clinical trial in which those patients could be
realistically enrolled, I think that would be ideal, but there isn’t,
and until there is you would have to decide whether a lobectomy
that can achieve an R0 resection with a 1% or 2%mortality is a rea-
sonable option. I would contend that it is.
Dr Cerfolio. Dr Altorki, if it was more than 1 station and re-
quired a pneumonectomy, do you agree that you wouldn’t do it?
Dr Altorki.Well, I think that the issue of multistation disease is
interesting, because it’s sometimes difficult to make that determi-
nation except intraoperatively.
Jean Deslauriers just told that he thought pneumonectomy is not
a great operation. I agree with that. But regardless of its physio-
logic impact on the patient, it is a marker of higher tumor burden.
At least in this study, the tumor bulk precluded treatment with
a sleeve lobectomy. So the idea that we’re going to somehow im-
prove survival for these patients by avoiding pneumonectomy and
doing sleeve lobectomy instead is an erroneous concept.ry c January 2011
Paul et al General Thoracic Surgery
G
T
SDr Marcin Zielinski (Zakopane, Poland). You showed very
nicely that some patients who do not have downstaging still
have some chance for 5-year survival. Twenty percent is quite
a good number of patients who can be long-term survivors. But
the problem is determining which patients without downstaging
have a chance for 5-year survival. In my institution, our policy is
to restage these patients who are candidates for an operation
with transcervical extended mediastinal lymphadenectomy, and
the patients in whom we are able to completely resect the nodes
and the number of the metastatic nodes is not so large are the
ones for whom we propose resection. I think this is the group we
choose with the best prognosis.
Of the patients without downstaging, with persistent N2 nodes,
who are the best candidates for an operation, and who can expect
5-year survival? What is your policy?
Dr Paul. Well, first of all, I don’t think our study is powered
enough to answer that question. Our policy has been to offer resec-
tion to patients who are young and have good performance status,
as long as we think, at least preoperatively looking at the scans,
that we can do an adequate R0 resection, take out most of the nodal
stations through a thoracotomy. I think it’s a similar answer towhat
you’re alluding to, that you can give them a good cleanout of the
mediastinum by looking at the preoperative scans.
Dr Zielinski.But can you predict whowill be the long-term sur-
vivors?
Dr Paul. We don’t have the data to predict that.
Dr Frank C. Detterbeck (New Haven, Conn). Dr Paul, very
nice study. I think this was very helpful. On the other hand, there
are a couple pieces of data that are missing that I think would be
helpful. One is just to elucidate very carefully what your philoso-
phy was during this relatively long period. You have kind of said
you didn’t restage, anybody that looked reasonable you took to
the operating room, but it would be nice to know a little bit
more precisely what the philosophy was, so that we can interpret
a little bit better what that means. Another piece of data that would
be very interesting would be how many patients you ended up giv-
ing preoperative therapy to and then did not take to the operating
room, just like Rob [Dr Cerfolio] had told us about 2 years ago, I
think it was. I think that would help us kind of gauge how selective
or nonselective you were. And the third piece of data that I would
love to have would be, about those patients on whom you decided
not to operate and who didn’t have brain metastases or progressive
disease, how did they do? If your 20% is better than 5%, then that’s
very convincing. If those patients actually also had 20%, then, of
course, it’s different.
Dr Paul. Dr Detterbeck, those are excellent questions, and ac-
tually when we originally approached this project, that was one of
our aims, to see what happens to all those patients who had media-
stinoscopy, got induction therapy, and never made it to surgery.
Unfortunately, we get patients referred to us from all over the
city who come from outside oncologists, and often they go back
to those outside oncologists, and it’s very difficult for us to assess
actually what happened to them, what their survival was. That is an
excellent question, and we are exploring ways of trying to answer
it.
Dr Altorki. I think that’s an important question, and I think the
judgment regarding resectability is made at time zero. If the patient
is deemed to have a resectable tumor, then he or she gets 3 or 4 cy-The Journal of Thoracic and Ccles of chemotherapy. I personally have not seen many patients
progress from resectability to unresectability within that period.
Dr Paul DeLeyn (Leuven, Belgium). Thank you very much for
this presentation. I think that many centers indeed have patients
with persistent N2 disease who have a survival of 20% or 25%,
but I would like to stress that mostly this is among selected pa-
tients, patients who had all aims of restaging, patients who had
a good response on PETor CT. So probably there is some selection.
I have a few questions. Your complete resectability rate is very
high when you compare it to the literature. Can you give us your
definition of complete resectability? The highest lymph node,
was it positive, negative?
Dr Paul. The highest lymph node being negative, as well as the
bronchial margin being negative.
Dr DeLeyn. But this is very high.
Dr Paul. It’s a high R0 rate. I recognize that.
Dr DeLeyn. Patients with persistent N2, did they get adjuvant
radiotherapy?
Dr Paul. Patients with persistent N2, if they could tolerate ad-
juvant radiotherapy, did get it.
Dr DeLeyn. How many patients?
Dr Paul. I don’t remember off the top of my head. It’s in the ar-
ticle. It’s probably on the order of about 60%.
Dr DeLeyn. And now that we have endobronchial ultrasonog-
raphy or endoscopic ultrasonography for primary staging, is your
current practice still to do mediastinoscopy?
Dr Paul. Our current policy is that we do not restage these pa-
tients if they—
Dr DeLeyn. I know, but do you still do mediastinoscopy?
Dr Paul.We still do mediastinoscopy on patients who have sus-
pected N2 disease.
Dr Cerfolio. He wants to know whether you’re saving the me-
diastinoscopy until after the neoadjuvant. So you’re starting off
with endobronchial ultrasonography and endoscopic ultrasonogra-
phy and doing the mediastinoscopy second?
Dr Paul. We have not started doing that quite yet.
Dr Joe B. Putnam (Nashville, Tenn). I enjoyed your presenta-
tion and was intrigued by the number of patients who underwent an
operation versus the denominator of about 450 patients who were
treated. These procedures represent the ultimate in personalized
surgical care, in that these patients were highly selected by the in-
dividual surgeon as capable of tolerating the operation, with a high
likelihood of R0 resection, which you so clearly demonstrated. As
you mentioned, these operations were done by accomplished sur-
geons, in an excellent center, supported by an experienced multi-
disciplinary team before the operation and a talented
multispecialty team during the operation as well. So I think these
findings reflect to some extent the advantages that come from a fo-
cused expertise in this area within a single hospital and may not be
generalizable to hospitals broadly across the United States or inter-
nationally. Recognizing this personal approach, many patients
have undergone chemotherapy and radiation in varying amounts
and in various intervals between cessation of radiation and the
time they appear in my outpatient clinic ready to have their tumor
removed! Could you comment on the number of patients who had
therapy outside your institution who were then operated on and on
the interval between the induction chemoradiotherapy being con-
cluded and the time the operation was performed?ardiovascular Surgery c Volume 141, Number 1 57
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SDr Paul. There were approximately 12 patients basically had
their staging done at an outside institution and received chemo-
therapy. As for the interval, I’m not sure. Our general policy has
been to wait about 3 to 4 weeks after the last dose of chemotherapy
before operating.
Dr L. Penfield Faber (Chicago, Ill). I compliment you on an
outstanding series that corresponds to our approach to clinically
advanced lung cancer at the Rush University Medical Center.
I noted that you only had 2 complete pathologic responses. In
other words, only 2 were sterilized, yet you had 49% down-
staged. This is a very nice result of downstaging. On the other
hand, we know that series that use ‘‘chemo-beamo,’’ or chemo-
radiation, have 18% to 22% complete pathologic responses.
These patients have long-term survival of 50%. So, I suggest
your results might improve with chemoradiation rather than che-
motherapy alone.
Dr Paul.We have a few thoughts on that. One is that our rate of
nodal downstaging is similar to that which was published in the in-
tergroup trial, which is roughly around 52%. In terms of recur-58 The Journal of Thoracic and Cardiovascular Surgerences, in most cases the site of first recurrence was distant.
About 78% to 80% of the patients had distant disease as the site
of first recurrence. In terms of local recurrence, rates were about
10% in the pneumonectomy group and 12% in the lobectomy
group. Our thoughts are that we don’t see how adding preoperative
radiation is going to improve on those results. I think that’s a con-
troversial topic, however, and that’s just our take on it.
Dr Faber. Different strokes for different folks. I have one his-
torical comment. If you look very carefully at the picture of the
pneumonectomy specimen removed by Evarts Graham, you will
note that there were N2 nodes present. So it began on day 1. Resect
those N2 nodes.
Dr Dominique H. Grunenwald (Paris, France). Excellent pre-
sentation. There is a question raised regarding the role of postop-
erative radiotherapy in N2 disease, and there is a place for a large
clinical trial addressing this issue. That is what we are trying to do
in Europe actually at this time, but with very great difficulties re-
garding inclusion of the patients, because N2 disease that is oper-
ated on and completely resected is rare.ry c January 2011
